As a result, IFN-γ is used worldwide for the treatment of more than 20 types of cancers including some hematological malignancies (chronic myeloid leukemia, B- and T-cell lymphoma) and certain solid tumors such as melanoma and Kaposi’s sarcoma [41], [42], [43]. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.